Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have earned an average recommendation of “Moderate Buy” from the nineteen analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $106.75.

Several brokerages have recently issued reports on GPCR. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, March 17th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Wolfe Research began coverage on Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Citizens Jmp lowered their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its stake in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after purchasing an additional 264,833 shares during the last quarter. BVF Inc. IL lifted its stake in Structure Therapeutics by 8.6% during the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $45.00 on Thursday. The firm has a market capitalization of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35. Structure Therapeutics has a 12 month low of $15.80 and a 12 month high of $94.90. The company’s 50 day simple moving average is $43.09 and its 200 day simple moving average is $57.53.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Sell-side analysts anticipate that Structure Therapeutics will post -1.64 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.